行情

MRNS

MRNS

Marinus Pharms
NASDAQ

实时行情|Nasdaq Last Sale

1.350
+0.020
+1.50%
盘后: 1.350 0 0.00% 16:00 10/18 EDT
开盘
1.380
昨收
1.330
最高
1.393
最低
1.300
成交量
103.47万
成交额
--
52周最高
6.27
52周最低
0.7700
市值
7,098.14万
市盈率(TTM)
-1.3665
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MRNS 新闻

  • Cantor Fitzgerald Assumes Marinus Pharmaceuticals at Overweight, Announces $7 Price Target
  • Benzinga.1天前
  • Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting
  • GlobeNewswire.2天前
  • The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch
  • Benzinga.3天前
  • The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch
  • Benzinga.3天前

更多

所属板块

制药
-0.90%
制药与医学研究
-0.94%

热门股票

名称
价格
涨跌幅

MRNS 简况

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
展开

Webull提供Marinus Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。